# Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)

> **NCT00081510** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 110 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Lonafarnib
- **DRUG:** Placebo
- **DRUG:** anastrozole

## Key facts

- **NCT ID:** NCT00081510
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2015-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00081510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00081510, "Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00081510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*